

Haematologica  
HAEMATOL/2015/135590  
Version 3

Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells

Disclosures: 1. This work was supported by grants from the University of Oslo, Oslo University Hospital Rikshospitalet, the South-Eastern Norway Regional Health Authority, The Swiss National Science Foundation, The Norwegian Cancer Society, The Research Council of Norway: CoE funding 179573/V40 and FriMedBio (204784/V40) for their grant support. 2. Last author: Ludvig Munthe - no such compensations/relationships. Bjarne Bogen holds patents on Vaccibody (tecnology, biologic/vaccine). Other coauthors: no financial interests. 3. No patents/copy rights or financial interests related to the study topic.

Contributions: APR, SB, SS, AO, DW, and LAM performed the experiments. GET performed patient selection, evaluation and gathered samples. APR, SB, SS, AO, DW, GET, BB, KT and LAM evaluated and analyzed the data. APR, SB, SS, KT and LAM designed experiments and wrote the manuscript.